November 21, 2016 - By kentuckypostne · 0 Comments
The stock of Viking Therapeutics Incorporated (NASDAQ:VKTX) registered a decrease of 22.32% in short interest. VKTX’s total short interest was 202,500 shares in November as published by FINRA. Its down 22.32% from 260,700 shares, reported previously. With 127,900 shares average volume, it will take short sellers 2 days to cover their VKTX’s short positions. The short interest to Viking Therapeutics Incorporated’s float is 1.86%. The stock decreased 0.85% or $0.01 on November 18, hitting $1.16. Viking Therapeutics Inc (NASDAQ:VKTX) has declined 4.96% since April 19, 2016 and is downtrending. It has underperformed by 8.82% the S&P500.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $23.00 million. The Firm focuses on the development of therapies for metabolic and endocrine disorders. It currently has negative earnings. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Out of 3 analysts covering Viking Therapeutics (NASDAQ:VKTX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $10 is the highest target while $6 is the lowest. The $8 average target is 589.66% above today’s ($1.16) stock price. Viking Therapeutics has been the topic of 3 analyst reports since April 7, 2016 according to StockzIntelligence Inc. The firm has “Buy” rating by H.C. Wainwright given on Thursday, April 7. Laidlaw maintained the stock with “Buy” rating in Thursday, August 11 report. The company was initiated on Tuesday, May 24 by Maxim Group.
Viking Therapeutics, Inc., incorporated on October 24, 2012, is a clinical-stage biopharmaceutical company. The Firm focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). The Company’s second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. The Company’s two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. VK2809 belongs to a family of prodrugs, which are cleaved in vivo to release potent thyromimetics. The Firm is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). X-ALD is an X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. The disease is caused by mutations in a peroxisomal transporter of very long chain fatty acids (VLCFA), known as the adenosine triphosphate binding cassette transporter D1, or ABCD1.
More notable recent Viking Therapeutics Inc (NASDAQ:VKTX) news were published by: Prnewswire.com which released: “Viking Therapeutics to Present at the 2016 BIO Investor Forum” on October 13, 2016, also Prnewswire.com with their article: “Viking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In …” published on September 26, 2016, Prnewswire.com published: “Viking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept …” on July 26, 2016. More interesting news about Viking Therapeutics Inc (NASDAQ:VKTX) were released by: Prnewswire.com and their article: “Viking Therapeutics Presents Positive Phase 1b Clinical Data on VK2809 in …” published on April 11, 2016 as well as Prnewswire.com‘s news article titled: “Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study …” with publication date: September 01, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.